Finding a balance in reduced toxicity hematopoietic stem cell transplantation for thalassemia: role of infused CD3+ cell count and immunosuppression
Open Access
- 7 February 2024
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (5) , 587-596
Abstract
We performed a retrospective analysis on 124 patients with transfusion-dependent thalassemia who were registered in the German pediatric registry for stem cell transplantation. All patients underwent first allogeneic hematopoietic stem cell transplantation (HSCT) between 2011 and 2020 and belonged mainly to Pesaro risk class 1–2. Four-year overall (OS) and thalassemia-free survival (TFS) were 94.5% ± 2.9% and 88.0% ± 3.4% after treosulfan-fludarabine-thiotepa- and 96.9% ± 3.1% (P = 0.763) and 96.9% ± 3.1% (P = 0.155) after busulfan-fludarabine-based conditioning. Mixed chimerism below 75% occurred predominantly in treosulfan-based regimens (27.5% versus 6.2%). OS and TFS did not differ significantly between matched sibling, other matched family and matched unrelated donor (UD) HSCTs (OS: 100.0%, 100.0%, 96.3% ± 3.6%; TFS: 96.5% ± 2.4%, 90.0% ± 9.5%, 88.9% ± 6.0%). However, mismatched UD-HSCTs performed less favorable (OS: 84.7% ± 7.3% (P = 0.029); TFS: 79.9% ± 7.4% (P = 0.082)). We generated a scoring system reflecting the risk to develop mixed chimerism in our cohort. The main risk-reducing factors were a high CD3+ cell count (≥6 × 107/kg) in the graft, busulfan-conditioning, pre-conditioning therapy and low-targeted ciclosporin A trough levels. Acute GvHD grade III-IV in treosulfan-based concepts predominantly occurred in patients with UD and reduced GvHD prophylaxis but not in the context of high CD3+ cell doses. Taken together, this information might be used to develop more risk-adapted HSCT regimens for thalassemia patients.Keywords
Funding Information
- Deutsche Kinderkrebsstiftung (DKS 2021.07, DKS 2021.07)
This publication has 30 references indexed in Scilit:
- Improved Clinical Outcomes of High Risk β Thalassemia Major Patients Undergoing a HLA Matched Related Allogeneic Stem Cell Transplant with a Treosulfan Based Conditioning Regimen and Peripheral Blood Stem Cell GraftsPLOS ONE, 2013
- French Multicenter 22-Year Experience in Stem Cell Transplantation for Beta-Thalassemia Major: Lessons and Future DirectionsTransplantation and Cellular Therapy, 2013
- Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alikeBone Marrow Transplantation, 2011
- HLA-matched sibling bone marrow transplantation for β-thalassemia majorBlood, 2011
- Unrelated Bone Marrow Transplantation for β‐Thalassemia Patients: The Experience of the Italian Bone Marrow Transplant GroupAnnals of the New York Academy of Sciences, 2005
- Monitoring Long‐Term Efficacy of Iron Chelation Treatment with Biomagnetic Liver SusceptometryAnnals of the New York Academy of Sciences, 2005
- Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonanceBlood, 2005
- New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 yearsBlood, 2004
- Bone Marrow Transplantation in Patients with ThalassemiaNew England Journal of Medicine, 1990
- CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,STransplantation, 1974